Stocktoria
Carl Zeiss Meditec AG AFX.DE
DE · Deutsche Börse Xetra · XETR · stock · Healthcare · website
Carl Zeiss Meditec AG financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €2.2B | €2.1B | €2.1B | €1.9B |
| Gross profit | €1.2B | €1.1B | €1.2B | €1.1B |
| R&D expense | €326.3M | €343.1M | €349.3M | €291.4M |
| SG&A expense | €626.5M | €569.2M | €504.1M | €438.1M |
| Operating income | €223.3M | €194.5M | €348.1M | €396.9M |
| Interest expense | €26.6M | €29.4M | €15.2M | €9.6M |
| Income tax | €51.5M | €60.7M | €120.6M | €107.6M |
| Net income | €141.2M | €178.7M | €290.4M | €293.9M |
| EPS (diluted) | €1.61 | €2.01 | €3.25 | €3.29 |
| Operating cash flow | €209.9M | €247.3M | €250.9M | €188.2M |
| Free cash flow | €133.3M | €95.1M | €137.0M | €106.2M |
| Cash & equivalents | €27.3M | €20.3M | €10.6M | €7.7M |
| Inventory | €497.0M | €536.2M | €519.6M | €382.7M |
| Goodwill | €969.7M | €982.5M | €415.8M | €429.6M |
| Total assets | €3.4B | €3.4B | €3.0B | €2.8B |
| Total debt | €132.5M | €151.3M | €155.7M | €127.9M |
| Total liabilities | €1.3B | €1.3B | €860.0M | €792.7M |
| Shareholders' equity | €2.1B | €2.0B | €2.2B | €2.0B |
| Share buybacks | €0 | €150.1M | €0 | — |
Growth · year-over-year · Revenue CAGR 5.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +7.8% | -1.1% | +9.8% | — |
| Net income growth | -21.0% | -38.5% | -1.2% | — |
| EPS growth | -19.9% | -38.2% | -1.2% | — |
| Free cash flow growth | +40.1% | -30.6% | +29.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · DE · as of 2025-09-30. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.